Full Text View
Tabular View
No Study Results Posted
Related Studies
Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine (ACP)
This study has been completed.
Study NCT00635037   Information provided by Federal University of São Paulo
First Received: March 5, 2008   Last Updated: March 12, 2008   History of Changes

March 5, 2008
March 12, 2008
June 2004
February 2005   (final data collection date for primary outcome measure)
Pain relief [ Time Frame: 1year ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00635037 on ClinicalTrials.gov Archive Site
compare the analgesic action of acupuncture and trigger point injection combined with cyclobenzaprine and dipyrone [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Same as current
 
Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine
Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine on Pain Relief of Patients With Myofascial Pain: Randomized Clinical Study

CONTEXT AND OBJECTIVE: Myofascial syndrome is the most frequent condition of chronic pain. The objective of the present study was to compare the analgesic action of acupuncture and trigger point injection combined with cyclobenzaprine and dipyrone.

DESIGN AND SETTING: A randomized study was performed at the Pain Clinic. METHODS: Thirty patients were divided into two groups: G1 received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h. G2 was submitted to classical and trigger point acupuncture twice a week. The patients were asked to continue physical exercise. The following parameters were evaluated: pain intensity rated on a numerical and verbal scale, quality of life before and four weeks after treatment, and quality of analgesia.

Among the 39 patients selected, nine (3 in group 1 and 6 in group 2) were excluded from the study because they did not attend the visits scheduled for the procedures and assessment or because they did not respond to the questionnaires.

 
Interventional
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Myofascial Pain Syndromes
Drug: bupivacaine and acupuncture
Experimental:

G1 (n=15)received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.

G2(n=15) was submitted to classical and trigger point acupuncture twice a week.

 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
30
November 2006
February 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:- patients of both genders

  • chronic myofascial syndrome (duration of more than three months),
  • ranging in age from 18 to 65 year,
  • pain intensity score of 3 or higher (rated on a numerical scale ranging from 0 to 10)

Exclusion Criteria:

  • patients with disc herniation,
  • osteoarthritis,
  • vertebral collapse,
  • temporomandibular joint dysfunction,
  • infection, -
  • tumors,
  • coagulopathy, -
  • psychiatric disease,
  • cognitive disorders.
  • Patients who had used any type of analgesic or muscle relaxant agent 15 days before the study and those taking anticoagulants
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Brazil
 
NCT00635037
Adriana Machado Issy/ Professor, Federal University of São Paulo
ACP myofascial, No grant
Federal University of São Paulo
 
Principal Investigator: Miriam CB Gazi, MD Federal University of Sao Paulo
Federal University of São Paulo
March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP